Drug-Coated Balloons Market Research Reveals Strong 15.6% CAGR Outlook Through 2030

The drug-coated balloons market is set to experience significant expansion in the coming years, driven by advancements in medical technology and growing clinical demand. These innovative devices play a critical role in vascular treatments, offering less invasive options and improved patient outcomes. Let's explore the current market size, key players, emerging trends, and segmentation details that define this rapidly evolving sector.

Strong Growth Forecast for the Drug-Coated Balloons Market by 2030
The market for drug-coated balloons is projected to reach $2.55 billion by 2030, expanding at a compound annual growth rate (CAGR) of 15.6%. This robust growth is driven primarily by increased application of drug-coated balloon therapies in coronary procedures. Additionally, the rising adoption of next-generation coating technologies, broader use of catheter-based interventions, and growing investments in vascular innovation are propelling the market forward. Patients and healthcare providers are increasingly favoring stent-free treatment approaches, adding further momentum to market expansion. Key trends expected to shape the industry include more widespread use of sirolimus-coated balloons, greater treatment of peripheral artery disease, growing preference for minimally invasive vascular therapies, continuous enhancement of drug-coating technologies, and a stronger focus on efficient drug delivery.

Download a free sample of the drug-coated balloons market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10829&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Leading Companies Driving the Drug-Coated Balloons Market
The drug-coated balloons landscape features several prominent companies actively shaping the market. These include Boston Scientific Corporation, Medtronic plc, Abbott Laboratories, B. Braun Melsungen AG, Terumo Corporation, Biotronik SE & Co. KG, Biosensors International Group Ltd, Concept Medical Inc., Acotec Scientific AG, Cardionovum GmbH, MedAlliance SA, iVascular SLU, Minvasys SAS, QT Vascular Ltd, Hexacath SAS, Cordis Corporation, MicroPort Scientific Corporation, Endocor GmbH, Orchestra BioMed Inc., Lepu Medical Technology Co. Ltd, Balton Sp. z o.o., and BrosMed Medical Co. Ltd. In a notable development in October 2023, Cordis US Corp acquired Med Alliance SA, aiming to integrate Med Alliance's SELUTION SLR sirolimus micro-reservoir drug-coated balloon into Cordis's coronary and peripheral offerings. This strategic move is intended to accelerate market access, enhance clinical development, and broaden treatment options for patients with coronary and peripheral vascular disease. Med Alliance SA operates out of Switzerland and specializes in drug-coated balloon technologies.

Technological Advances Set to Shape Future Opportunities in Drug-Coated Balloons
Industry leaders are focusing heavily on enhancing drug-coated balloon technologies, particularly paclitaxel-coated balloon catheters. These devices release the drug paclitaxel into the artery walls during inflation, helping prevent restenosis-the re-narrowing of vessels after angioplasty-especially in coronary in-stent restenosis cases. The ongoing improvements aim to boost treatment effectiveness, patient outcomes, and reduce complications linked to traditional therapies. For example, in March 2024, Boston Scientific Corporation received US Food and Drug Administration (FDA) approval for its AGENTTM Drug-Coated Balloon, designed specifically for treating coronary in-stent restenosis in patients with coronary artery disease. This approval highlights the continuous innovation and regulatory support fueling market growth.

View the full drug-coated balloons market report:
https://www.thebusinessresearchcompany.com/report/drug-coated-balloons-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Key Segments Defining the Global Drug-Coated Balloons Market
The global drug-coated balloons market can be broken down into several vital segments. By product type, the market is categorized into drug-coated balloons for peripheral artery disease and those for coronary artery disease. Regarding drug types, paclitaxel and sirolimus are the primary options used in these balloons. The end-user segment consists of hospitals, cardiac catheterization laboratories, and ambulatory surgical centers. Further subcategories include paclitaxel-coated and sirolimus-coated balloons for both peripheral artery disease and coronary artery disease, allowing for a detailed understanding of therapeutic applications and technology preferences across different patient groups.

What's new in our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel dashboards
• Market hotspots infographics
• Key technologies and future trends
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.